217 related articles for article (PubMed ID: 28315136)
1. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
2. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion.
Lew JL; Zhao A; Yu J; Huang L; De Pedro N; Peláez F; Wright SD; Cui J
J Biol Chem; 2004 Mar; 279(10):8856-61. PubMed ID: 14684751
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
[TBL] [Abstract][Full Text] [Related]
4. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
5. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
8. Consumption of soy protein isolate reduces hepatic SREBP-1c and lipogenic gene expression in wild-type mice, but not in FXR-deficient mice.
Hashidume T; Sasaki T; Inoue J; Sato R
Biosci Biotechnol Biochem; 2011; 75(9):1702-7. PubMed ID: 21897047
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Campana G; Pasini P; Roda A; Spampinato S
Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
[TBL] [Abstract][Full Text] [Related]
10. The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing.
Mroz MS; Lajczak NK; Goggins BJ; Keely S; Keely SJ
Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G378-G387. PubMed ID: 29351391
[TBL] [Abstract][Full Text] [Related]
11. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
[TBL] [Abstract][Full Text] [Related]
12. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
13. Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues.
Watanabe S; Fujita K
Lipids; 2014 Oct; 49(10):963-73. PubMed ID: 25189147
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
15. Bile acid nuclear receptor FXR and digestive system diseases.
Ding L; Yang L; Wang Z; Huang W
Acta Pharm Sin B; 2015 Mar; 5(2):135-44. PubMed ID: 26579439
[TBL] [Abstract][Full Text] [Related]
16. Characterization of individual bile acids in vivo utilizing a novel low bile acid mouse model.
Taylor R; Yang Z; Henry Z; Capece G; Meadows V; Otersen K; Basaly V; Bhattacharya A; Mera S; Zhou P; Joseph L; Yang I; Brinker A; Buckley B; Kong B; Guo GL
Toxicol Sci; 2024 May; 199(2):316-331. PubMed ID: 38526215
[TBL] [Abstract][Full Text] [Related]
17. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.
Hu X; Bonde Y; Eggertsen G; Rudling M
J Intern Med; 2014 Jan; 275(1):27-38. PubMed ID: 24118394
[TBL] [Abstract][Full Text] [Related]
18. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
Li X; Yuan Z; Liu R; Hassan HM; Yang H; Sun R; Zhang L; Jiang Z
Toxicol Appl Pharmacol; 2016 Nov; 311():12-25. PubMed ID: 27743861
[TBL] [Abstract][Full Text] [Related]
19. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine.
Zollner G; Fickert P; Fuchsbichler A; Silbert D; Wagner M; Arbeiter S; Gonzalez FJ; Marschall HU; Zatloukal K; Denk H; Trauner M
J Hepatol; 2003 Oct; 39(4):480-8. PubMed ID: 12971955
[TBL] [Abstract][Full Text] [Related]
20. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
Yu DD; Andrali SS; Li H; Lin M; Huang W; Forman BM
Bioorg Med Chem; 2016 Sep; 24(18):3986-3993. PubMed ID: 27372840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
